Avenacy Marks a Milestone at CPHI Milan 2024
Avenacy, a dedicated specialty pharmaceutical company, is eager to reflect on its progress and growth during its inaugural year of operations. The firm has made significant advancements in improving patient access to vital injectable medications.
First Year Achievements
Since it launched, Avenacy has successfully introduced 13 injectable products to the U.S. market, addressing urgent needs within the healthcare system. This exceptional range aims to fill crucial gaps in the supply chain.
Highlights of Product Launches
Some of the standout products released include:
- Melphalan Hydrochloride for Injection
- Bivalirudin for Injection
- Fosaprepitant for Injection
- Fulvestrant Injection
- Furosemide for Injection
- Desmopressin Acetate for Injection
- Eptifibatide for Injection
- Magnesium Sulfate in Water for Injection
- Isoproterenol Hydrochloride Injection, USP
- Tranexamic Acid Injection, USP
- Prochlorperazine Edisylate Injection, USP
- Palonosetron Hydrochloride Injection, USP
- Metoclopramide Injection, USP
Focus on Quality and Safety
Avenacy’s achievements rest on its commitment to quality and safety. The company has designed unique packaging and labeling to assist healthcare providers in making informed medication decisions. This initiative is vital in reducing administration errors and avoiding incorrect dosages.
Innovative Approaches to Patient Care
To boost patient safety and improve care efficiency, Avenacy offers ready-to-use formulations of essential medications. These innovations target common issues with dosing inaccuracies and help streamline healthcare processes overall.
Looking Ahead: Growth and Global Presence
As it looks to the future, Avenacy plans to broaden its business model and partnerships during the upcoming CPHI Milan 2024 Conference. Scheduled for October 8-10, this significant event will provide a platform for the company to present its unique approach and connect with potential partners and investors.
Leadership Insights
Jeff Yordon, the Co-Founder and CEO of Avenacy, expressed his pride in the company's growth and clear direction. He highlighted the firm’s commitment to enhancing patient care by focusing strategically on bridging the gaps in critical medication availability. Under the guidance of investor Dr. Patrick Soon-Shiong, Avenacy is well-positioned for considerable expansion.
About Avenacy
Founded in 2023, Avenacy is a U.S.-based specialty pharmaceutical company that aims to deliver essential injectable medications. The company serves a variety of healthcare settings, from acute care hospitals to outpatient clinics. Avenacy maintains a strong pipeline of high-quality, FDA-approved products, demonstrating its dedication to supporting the dynamic drug supply chain and ensuring exceptional patient care.
Located in Schaumburg, IL, Avenacy encourages inquiries from individuals looking to learn more about its products and services. For further information, feel free to visit http://www.avenacy.com/.
Frequently Asked Questions
What is Avenacy?
Avenacy is a specialty pharmaceutical company committed to providing essential injectable medications across various healthcare settings.
What products has Avenacy launched?
Avenacy has launched a total of thirteen injectable products, including notable items like Melphalan and Bivalirudin.
Where will Avenacy showcase its accomplishments?
Avenacy plans to present its achievements from the first year at the CPHI Milan 2024 Conference.
Who leads Avenacy as CEO?
Jeff Yordon serves as the Co-Founder and CEO of Avenacy.
When was Avenacy founded?
Avenacy was founded in 2023.
